Literature DB >> 11532992

Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.

A Wyttenbach1, J Swartz, H Kita, T Thykjaer, J Carmichael, J Bradley, R Brown, M Maxwell, A Schapira, T F Orntoft, K Kato, D C Rubinsztein.   

Abstract

Huntington's disease (HD) is one of 10 known diseases caused by a (CAG)(n) trinucleotide repeat expansion that is translated into an abnormally long polyglutamine tract. We have developed stable inducible neuronal (PC12) cell lines that express huntingtin exon 1 with varying CAG repeat lengths under doxycycline (dox) control. The expression of expanded repeats is associated with aggregate formation, caspase-dependent cell death and decreased neurite outgrowth. Post-mitotic cells expressing mutant alleles were more prone to cell death compared with identical cycling cells. To determine early metabolic changes induced by this mutation in cell models, we studied changes in gene expression after 18 h dox induction, using Affymetrix arrays, cDNA filters and adapter-tagged competitive PCR (ATAC-PCR). At this time point there were low rates of inclusion formation, no evidence of mitochondrial compromise and no excess cell death in the lines expressing expanded compared with wild-type repeats. The expression profiles suggest novel targets for the HD mutation and were compatible with impaired cAMP response element (CRE)-mediated transcription, which we confirmed using CRE-luciferase reporter assays. Reduced CRE-mediated transcription may contribute to the loss of neurite outgrowth and cell death in polyglutamine diseases, as these phenotypes were partially rescued by treating cells with cAMP or forskolin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532992     DOI: 10.1093/hmg/10.17.1829

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  76 in total

1.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.

Authors:  Barbara L Apostol; Alexsey Kazantsev; Simona Raffioni; Katalin Illes; Judit Pallos; Laszlo Bodai; Natalia Slepko; James E Bear; Frank B Gertler; Steven Hersch; David E Housman; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

2.  Polyalanine and polyserine frameshift products in Huntington's disease.

Authors:  J E Davies; D C Rubinsztein
Journal:  J Med Genet       Date:  2006-06-26       Impact factor: 6.318

Review 3.  Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution.

Authors:  Massimo Stefani; Christopher M Dobson
Journal:  J Mol Med (Berl)       Date:  2003-08-27       Impact factor: 4.599

4.  Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival.

Authors:  Junghee Lee; Chun-Hyung Kim; David K Simon; Lyaylya R Aminova; Alexander Y Andreyev; Yulia E Kushnareva; Anne N Murphy; Bonnie E Lonze; Kwang-Soo Kim; David D Ginty; Robert J Ferrante; Hoon Ryu; Rajiv R Ratan
Journal:  J Biol Chem       Date:  2005-10-05       Impact factor: 5.157

5.  A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.

Authors:  Marianne R Smith; Adeela Syed; Tamas Lukacsovich; Judy Purcell; Brett A Barbaro; Shane A Worthge; Stephen R Wei; Giuseppe Pollio; Letizia Magnoni; Carla Scali; Luisa Massai; Davide Franceschini; Michela Camarri; Marco Gianfriddo; Enrica Diodato; Russell Thomas; Ozgun Gokce; S J Tabrizi; Andrea Caricasole; Bernard Landwehrmeyer; Liliana Menalled; Carol Murphy; Sylvie Ramboz; Ruth Luthi-Carter; Goran Westerberg; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-01-16       Impact factor: 6.150

6.  Heat shock transcription factor-1 suppresses apoptotic cell death and ROS generation in 3-nitropropionic acid-stimulated striatal cells.

Authors:  Yong-Joon Choi; Ji-Yeon Om; Nam-Ho Kim; Ji-Eun Chang; Jun Ho Park; Ji-Young Kim; Hee Jae Lee; Sung-Soo Kim; Wanjoo Chun
Journal:  Mol Cell Biochem       Date:  2012-12-06       Impact factor: 3.396

7.  Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease.

Authors:  Benjamin R Underwood; Sara Imarisio; Angeleen Fleming; Claudia Rose; Gauri Krishna; Phoebe Heard; Marie Quick; Viktor I Korolchuk; Maurizio Renna; Sovan Sarkar; Moisés García-Arencibia; Cahir J O'Kane; Michael P Murphy; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2010-06-21       Impact factor: 6.150

8.  Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.

Authors:  Carmela Giampà; Daunia Laurenti; Serenella Anzilotti; Giorgio Bernardi; Frank S Menniti; Francesca Romana Fusco
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

9.  Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease.

Authors:  Daniel W Neef; Michelle L Turski; Dennis J Thiele
Journal:  PLoS Biol       Date:  2010-01-19       Impact factor: 8.029

10.  Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors.

Authors:  M Futter; H Diekmann; E Schoenmakers; O Sadiq; K Chatterjee; D C Rubinsztein
Journal:  J Med Genet       Date:  2009-05-17       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.